Furthermore, SGLT-2 inhibition has been shown to improve outcomes in people with diabetes with high cardiovascular risk, and in people with heart failure across the spectrum of left ventricular ejection fraction [4–6]. The gene discussed is SLC5A2; the disease is heart failure.